Caroline Seymour | Authors


Post-Hoc Analysis of Pivotal Trial Demonstrates Safety of Selpercatinib in RET-Altered Advanced Solid Tumors

April 27, 2021

Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.